REV 5901

REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma[1][2][3].

Product Specifications

CAS Number

[101910-24-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Leukotriene Receptor; Lipoxygenase

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rev-5901.html

Purity

99.9

Solubility

DMF : 36 mg/mL (ultrasonic; warming)

Smiles

OC(CCCCC)C1=CC=CC(OCC2=NC3=CC=CC=C3C=C2)=C1

Molecular Formula

C22H25NO2

Molecular Weight

335.44

Precautions

H315, H319, H335

References & Citations

[1]Inwegen RGV, et, al. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241 (1) :117-24.|[2]Anderson G, et, al. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol. 1988 Aug;94 (4) :1115-22. |[3]Paskaš S, et al. Carborane-Based Analog of Rev-5901 Attenuates Growth of Colon Carcinoma In Vivo. Molecules. 2022 Jul 14;27 (14) :4503.